VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
RVMDRevolution Medicines, Inc.
$162.99$34.7B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksRVMDRevenue History

RVMD logoRevolution Medicines, Inc. (RVMD) Revenue History

Annual and quarterly revenue from 2017 to present

TTM Revenue$0
YoY Growth—
Q1 2026$0
Revenue CAGR
3Y—
→
5Y—
→
10Y—
Best Fiscal Year$50.0M (2019)
Best Quarter$15.3M (Q4 2022)

RVMD Revenue Over Time (2017–2025)

RVMD Revenue Growth History

2 of 6 years with positive growth
Annual Revenue Growth · Each cell = one fiscal year
2017—
2018—
2019+148.2%
2020-14.1%
2021-31.6%
2022+20.4%
2023-67.3%
2024-100.0%
2025—
FY2017 revenue growth
N/A
FY2018 revenue growth
N/A
FY2019 revenue growth
+148.2%
FY2020 revenue growth
-14.1%
FY2021 revenue growth
-31.6%
FY2022 revenue growth
+20.4%
FY2023 revenue growth
-67.3%
FY2024 revenue growth
-100.0%
FY2025 revenue growth
N/A
DeclineStrong growth
Best: +148.2% (FY2019)Worst: -100.0% (FY2024)
Recent Quarterly Revenue & YoY Growth
QuarterRevenueYoY
Q1 2026$0—
Q4 2025$0—
Q3 2025$0—
Q2 2025$0—
Q1 2025$0—
Q4 2024$0-100.0%
Q3 2024$0—
Q2 2024$0-100.0%
Seasonal Revenue Pattern (fiscal quarters)
Q1
36%
Q2
28%
Q3
11%
Q4
26%

Multi-year avg. share of annual revenue by fiscal quarter

Revenue Breakdown (FY 2022)

RVMD's revenue distribution by segment and geography for fiscal year 2022

By Product/Segment

Collaboration Revenue Member100.0%

RVMD Revenue Analysis (2017–2025)

Current Revenue & Growth

As of June 20, 2026, Revolution Medicines, Inc. (RVMD) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue

Historical Growth Trajectory

RVMD's historical revenue data shows various trends over time. Revolution Medicines, Inc.'s highest annual revenue of $50.0 million was recorded in 2019.

Revenue by Segment

RVMD's revenue is primarily driven by Collaboration Revenue Member (100%). With over half of revenue concentrated in Collaboration Revenue Member, the company has a focused business model while developing other growth vectors.

Peer Comparison

Compared to Healthcare sector peers — including MRSN (-4.8% YoY), ARVN (-79.1% YoY), and BDTX (-100.0% YoY). Compare RVMD vs MRSN →

RVMD Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
RVMD logoRVMDCurrent$0---
MRSN logoMRSN$40M-4.8%-0.8%-181.1%
ARVN logoARVN$263M-79.1%+58.9%-43.8%
BDTX logoBDTX$70M-100.0%-28.4%
TNGX logoTNGX$62M+39.0%+52.1%-178.4%
Best in groupLowest in group

RVMD Historical Revenue Data (2017–2025)

1–9 of 9 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$0-$-16,558,000-$-1,182,369,000-
2024$0-100.0%$0-$-689,524,000-
2023$11.6M-67.3%$11.6M100.0%$-487,185,000-4207.1%
2022$35.4M+20.4%$35.4M100.0%$-258,279,000-730.0%
2021$29.4M-31.6%$29.4M100.0%$-188,008,000-639.7%
2020$43.0M-14.1%$43.0M100.0%$-110,697,000-257.5%
2019$50.0M+148.2%$50.0M100.0%$-54,120,000-108.2%
2018$20.2M-$20.2M100.0%$-40,329,000-200.0%
2017$0-$-26,586,000-$-31,129,000-
Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into RVMD consensus models and risk factors.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

9+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

RVMD — Frequently Asked Questions

Quick answers to the most common questions about buying RVMD stock.

Is RVMD's revenue growth accelerating or slowing?

RVMD TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is RVMD's revenue history from 2017 to 2026?

Revolution Medicines, Inc. (RVMD) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.

What is RVMD's long-term revenue growth rate (CAGR)?

Revolution Medicines, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for RVMD.

Why does RVMD's quarterly revenue fluctuate?

RVMD quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Revolution Medicines, Inc.'s revenue data from 2017 to 2026 shows full historical quarterly detail on this page.

How is RVMD's revenue distributed by segment?

RVMD reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.

How does RVMD's revenue compare to industry peers?

Revolution Medicines, Inc. (RVMD) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.